Corvus reports soquelitinib Phase 1 atopic dermatitis data: 26% IGA 0/1, 37% EASI 75 vs 0% placebo

Corvus Pharmaceuticals, Inc.

19 soquelitinib patients: 26% achieved IGA 0/1, 37% achieved EASI 75 at day 28.
Placebo group (n=7) had 0% achieving IGA 0/1 or EASI 75.
No significant safety issues; all 10 Cohort 2 patients completed 28-day full 200 mg once-daily dose.
Cohort 2 fully enrolled (N=16); full results from all four cohorts expected Q2 2025.
Soquelitinib 200 mg twice-daily dose being studied in Phase 3 for peripheral T cell lymphoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.